When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Ahead of the 2025 J.P. Morgan Healthcare Conference scheduled to take place in a few days, Oppenheimer named five potential buyout candidates in biotech on Friday, naming obesity drug developer Viking ...

The lawsuit was brought against the FDA after the agency declared an end to the shortage that allowed pharmacies to sell compound versions of the popular weight loss drugs, but Eli Lilly said it ...

Anticipation builds for Eli Lilly's oral obesity drug orforglipron's trial results in 2025, following Novo Nordisk's ...

As expected by many, Eli Lilly And Co (NYSE:LLY) filed a motion to intervene as a defendant in a case between the Outsourcing ...

According to a recent release from GlobalData, Eli Lilly’s obesity offering could become a potential leader in the market.

There are now more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

Axios Visuals The number of prescriptions for GLP-1 drugs jumped roughly 10% in 2024, according to insurance claims data provided to Axios by health analytics company PurpleLab. Why it matters: The ...